A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2024-09-17
DOI
https://doi.org/10.3389/fcvm.2024.1445970
Citations
1
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.40

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Penghui Liu
1 citations
Frontiers in Cardiovascular Medicine
Atrial Fibrillation Management and Outcomes
0.40
article

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Penghui Liu
article en
1 citations

Abstract

No abstract available for this paper.
Frontiers in Cardiovascular MedicineVol. 11
Henan University Huaihe Hospital and Huaihe Clinical Institute (CN)
Zhengzhou University
Good health and well-being
Openalex Percentile: Top 33%
Atrial Fibrillation Management and Outcomes
0.40
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk — Penghui Liu · Frontiers in Cardiovascular Medicine (2024) | TGRS Research Map | TGRS